A
Axel Ullrich
Researcher at Max Planck Society
Publications - 436
Citations - 63142
Axel Ullrich is an academic researcher from Max Planck Society. The author has contributed to research in topics: Receptor tyrosine kinase & Tyrosine kinase. The author has an hindex of 124, co-authored 436 publications receiving 61445 citations. Previous affiliations of Axel Ullrich include Institute of Molecular and Cell Biology & Agency for Science, Technology and Research.
Papers
More filters
Journal ArticleDOI
Visceral obesity and inflammation markers in relation to serum prostate volume biomarkers among apparently healthy men.
Majed S. Alokail,Nasser M. Al-Daghri,Omar S. Al-Attas,Khalid M. Alkharfy,Shaun Sabico,Axel Ullrich +5 more
TL;DR: In this paper, the associations of adiponectin and WHR strengthen the link between insulin resistance and visceral adiposity to prostate volume markers among apparently healthy Arab men, using a cross-sectional study.
Journal ArticleDOI
Molecular Targets in Cancer Therapy and Their Impact on Cancer Management
TL;DR: The development of the first target-specific agents was slow because of the many new challenges faced by scientists and clinicians, but they are now commonly used to treat certain tumors and it seems likely that these target-based agents will revolutionize the way the authors treat and perceive cancer.
Journal ArticleDOI
Elimination of B-RAF in Oncogenic C-RAF-expressing Alveolar Epithelial Type II Cells Reduces MAPK Signal Intensity and Lung Tumor Growth
Emanuele Zanucco,Nefertiti El-Nikhely,Rudolf Götz,Katharina Weidmann,Verena Pfeiffer,Rajkumar Savai,Werner Seeger,Axel Ullrich,Ulf R. Rapp +8 more
TL;DR: Data indicate that B-RAF is an important factor in oncogenic C- RAF-mediated tumorigenesis, and mutation of Ser-621 in C-RAf BxB abrogated in vitro the dimerization with B-raF and blocked the ability to activate the MAPK cascade.
Journal ArticleDOI
Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors
Bálint Szokol,Pál Gyulavári,Ibolya Kurko,Ferenc Baska,Csaba Szántai-Kis,Zoltán Greff,Zoltan Örfi,István Peták,Kinga Pénzes,Robert Torka,Axel Ullrich,Laszlo Orfi,Tibor Vántus,György Kéri +13 more
TL;DR: Dual EGFR/c-Met inhibitors are identified and designed and novel N-[4-(quinolin-4-yloxy)-phenyl]-biarylsulfonamide derivatives are designed, which inhibit the c-Met receptor and both the wild-type and the activating mutant EGFR kinases in nanomolar range.
Journal ArticleDOI
Exclusive expression of the receptor tyrosine kinase MDK4 in skeletal muscle and the decidua.
TL;DR: Mouse developmental kinase 4 (MDK4), a novel receptor tyrosine kinase (RTK), was identified via degenerate primer screening of mouse embryo cDNA and Immunofluorescence data indicated that MDK4 protein production begins with myoblasts elongation and is maintained throughout myotube formation.